Bajaj Healthcare hits new high

Bajaj Healthcare, which had closed yesterday at Rs.636.05, opened a tad lower at Rs.635.65 but soon rose to hit a new high at Rs.675. Volumes are up 6.5 times.

The company announced today morning the launch of “Posaconazole API” used in treating Mucormycosis (Black Fungus) infection in Covid-19 patients.

It has received approval from FDA Gandhi Nagar, Gujarat (India), to manufacture and market “Posaconazole API” as approved medication for treating Mucormycosis in India and it will commence its commercial production from 1 st week of June 2021.

The company has successfully developed the active pharmaceutical ingredient (API) for Posaconazole through its own in-house R&D team. The drug will be available as a prescription-based medication, with recommended doses.

Three weeks ago, company launched “Ivejaj" (Ivermectin) an oral AntiParasitic Drug used in control & treatment for Covid.  And it also launched antiviral drug favipiravir for the treatment of 'mild to moderate covid-19 patients.